TITLE:
HORIZON-PFT: Pivotal Fracture Trial

CONDITION:
Osteoporosis

INTERVENTION:
Zoledronic Acid

SUMMARY:

      HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once
      per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral
      fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to
      determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 65 Years to 89 Years
Criteria:

        Inclusion Criteria:

          -  Female, 65-89 years old

          -  No history of severe liver, kidney or eye disease

        Exclusion Criteria:

          -  Current bisphosphonate users such as Aredia (pamidronate), Didronel (etidronate),
             Fosamax (alendronate), Actonel (risedronate), Skelid (tiludronate)

          -  Using hip protectors

        Other protocol-defined inclusion/exclusion criteria may apply.
      
